As per our research report, the size of the global histone deacetylase inhibitors market to worth USD 152 Million by 2025, growing at a CAGR of 8.11% from 2020 to 2025.
Histone Deacetylase Inhibitors are classified in the product such as DEAE-Dextron, calcium phosphate, Activated dendrimers, etc. and the equipment-liposomes, microinjection and laserfection. HDACs play an important role in the regulation of gene expression. HDACs are present in the high amount in many types of tumor.
The adoption of innovative technology advancements, improvements in the healthcare infrastructure, and the rapid growth rate in government initiatives in pharmaceutical & biotechnology companies for the drug developments are greatly influencing the demand of the market.
Collaborations between the companies & lunch of innovative products are increasing the growth of the market. Increase in cancer patients and other illness with effective results in treatment is driving the market of HDAC market. Investment in the research and development activities surges the market. HDAC reduce the rate of angiogenesis & increase the immune response, which is providing scope for market growth.
A growing number of people who are suffering from cancer is a crucial factor propelling the demand of the market. Increasing support from the government and rise in investments on research and development in the cancer treatment field is driving the demand of the market. Huge demand for achieving maximum productivity with very less cost are the major factors that are responsible for boosting up the market growth. The manufacturers of histone deacetylase inhibitors collaborate with other companies, and this is also one of the factors leading the market growth.
Need to make better changes in the effectiveness of new treatments, growing mergers and collaborations are also accelerating the market growth. The rise in the common increase of cancer is also bolstering the market. Also, research and development related to disorders or nerves and other diseases are driving the market forward. Funds from government and other organizations are also boosting the market. Pharmaceutical industries spending huge amount of money on R&D and also growing prevalence for diagnosing the disease at an early stage are ascribed to bolster the growth rate of the market.
Lack of reimbursement policies in undeveloped countries is hindering the Histone deacetylase inhibitors market growth. Lack of knowledge among the people may limit the growth rate of this market. Strict rules and guidelines to be followed for the product to be approved are also the factors that restrain market growth.
Less awareness in the patients for the treatment of cancer & chronic diseases are hampering the market growth. The rising value of raw material required for the production & manufacturing of HDACs has reduced the market growth for the future. HDACs side effects such as toxicity after consumption are also a factor impeding the demand of the market. Some factors that influence in the HDACs market are less skilled professionals in the well-developed countries.
RECENT MARKET DEVELOPMENTS
On November 29, 2019, the Shenzhen Chipscreen Biosciences Company. Ltd. launched an innovate product named Epidaza (Chidamide), it's an oral subtype of histone deacetylase inhibitors. This product is used for the treatment of HER2- advance negative breast cancer. Shenzhen had received the approval from National Medical Products Administration.
On November 19, 2019, Alkermes, the Irish biopharmaceutical company announced the acquisition of Rodin Therapeutic of worth US $ 950million. Rodin Therapeutics developed the small molecule therapy for the synaptopathies. They also designed the molecules to target the histone deacetylase inhibitors. Inhibition decreases the toxicity of haematologic safety.
Market Size Available
2019 to 2025
2020 to 2025
By Class, Application and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This market research report on Global Histone Deacetylase Inhibitors Market has been segmented based on the class, application and region.
Histone Deacetylase Inhibitors Market - By Class:
Histone Deacetylase Inhibitors Market – By Application
North America accounted for the largest share in the global market. It is expected to retain its lead till 2022. Higher adoption rates in this region are the cause attributable to the observable trend mentioned above. Europe comes second by market share. It is however anticipated to experience slow growth in the forecast period.
Europe stands second followed by North America. This region is likely to have high CAGR value during the period and is estimated to reach a million dollar USD. In the European region, the UK is expected to lead the market. Adoption of advanced technology in the healthcare centres is propelling the demand of the market.
The Asia Pacific is poised for a robust growth trajectory in the forecast period. China will spearhead this growth spurt. Latin America and MEA continue to tail these leading regional markets in the forecast period.
TOP COMPANIES IN THE MARKET
Key players leading the global histone deacetylase inhibitors market profiled in the report are Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celeron Therapeutics, Envivo Pharmaceuticals and Pfizer, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Class I HDACs
5.1.3 Class II HDACs
5.1.4 Class III HDACs
5.1.5 Y-o-Y Growth Analysis, By Class
5.1.6 Market Attractiveness Analysis, By Class
5.1.7 Market Share Analysis, By Class
5.2.3 Central Nervous System Disorders
5.2.4 Other Diseases
5.2.5 Y-o-Y Growth Analysis, By Application
5.2.6 Market Attractiveness Analysis, By Application
5.2.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Class
22.214.171.124 By Application
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Class
184.108.40.206 By Application
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Class
22.214.171.124 By Application
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Acetylon Pharmaceuticals
8.3 Celleron Therapeutics
8.4 Envivo Pharmaceuticals
8.6 Merck & Co.
8.8 Eisai Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures